Each year about 46,500 men are diagnosed with prostate cancer in Britain, and about 11,000 people die from the disease. Each year about 46,500 men are diagnosed with prostate cancer in Britain, and about 11,000 people die from the disease.
Written by  Jun 04, 2017 - 107 Views

Prostate cancer, a new drug may save more lives

Experimentation about the treatment of Prostate Cancer has revealed a serious drug that can save more patients in early stages.

The trial focused on #Avratronone as an additional treatment for patients with prostate cancer who were about to start a long-term hormonal therapy.

The results of the trial were published in the New England Journal of Medicine.

Avratronone, also known as Xetega, is a hormone therapy.

Avratiron, the opposite of chemotherapy that kills cancer cells, prevents more testosterone from reaching the prostate gland to stifle tumor growth.

The trial included nearly 2,000 patients.

Half of the men were treated with hormones, while the other half received hormone therapy and Avratronone.

Of the 1,917 men in the trial, 184 died in the mixed group compared with 262 in the hormone-only group.

Professor Nicholas James of the University of Birmingham, who led the research, says: "Epreation is actually used to treat some men who have spread the disease in their bodies but our results show a lot of men can benefit."

Each year about 46,500 men are diagnosed with prostate cancer in Britain, and about 11,000 people die from the disease.

Leave a comment

Featured Posts

Contact Info

  • Vision, site looking away from politics, in the history of humanity, is also looking at the history of public figures.

  • Reliance on the picture, and video, "first evidence".

  • (216) 5353 - 3320 / (2016) 7137 - 1447
  • This email address is being protected from spambots. You need JavaScript enabled to view it.
Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…